Holen Sie sich die Stockscreener-App
0.5847
3.98%
0.0224
Handel nachbörslich:
.57
-0.0147
-2.51%
Schlusskurs vom Vortag:
$0.5623
Offen:
$0.5637
24-Stunden-Volumen:
74,623
Relative Volume:
0.15
Marktkapitalisierung:
$2.54M
Einnahmen:
$7,500
Nettoeinkommen (Verlust:
$-9.84M
KGV:
-0.1021
EPS:
-5.7263
Netto-Cashflow:
$-9.25M
1W Leistung:
+16.06%
1M Leistung:
-35.03%
6M Leistung:
-55.02%
1J Leistung:
-89.59%
1-Tages-Spanne:
$0.5603
$0.616
1-Wochen-Bereich:
$0.5038
$0.616
52-Wochen-Spanne:
$0.5038
$9.60
Oragenics Inc Stock (OGEN) Company Profile
Firmenname
Oragenics Inc
Sektor
Branche
Telefon
813-286-7900
Adresse
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.5847 | 2.44M | 7,500 | -9.84M | -9.25M | -5.7263 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Oragenics Inc Aktie (OGEN) Neueste Nachrichten
0A64.IL,0P0001LL1F,111 (0A64.IL) Latest Press Releases & Corporate News - Yahoo! Finance Canada
Oragenics Inc (UAV.BE) Stock Price, News, Quote & History - ca.finance.yahoo.com
OGEN Stock Price, Quote & Chart | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
Oragenics Sets New 2025 Annual Shareholder Meeting Date - The Globe and Mail
Oragenics: CEO Highlights "Undervalued" Pipeline Amid Significant Insider Sale of 35% Ownership - Bitget
Oragenics (OGEN) schedules 2025 shareholder meeting and sets May 1, 2026 proposal cutoff - Stock Titan
Risks Report: What is the target price for Oragenics Inc stockDollar Strength & Real-Time Stock Movement Alerts - baoquankhu1.vn
Oragenics Receives Going Concern Qualification Amid Clinical Trial Preparations - citybuzz -
Oragenics (OGEN) Reports Going Concern Risk in Latest Audit - gurufocus.com
OGEN SEC FilingsOragenics 10-K, 10-Q, 8-K Forms - Stock Titan
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation - globenewswire.com
Volume Recap: Is Oragenics Inc vulnerable to short sellers2026 Support & Resistance & Long Hold Capital Preservation Tips - baoquankhu1.vn
[EFFECT] ORAGENICS INC SEC Filing - Stock Titan
If You Invested $1,000 in Oragenics (OGEN) - Stock Titan
Growth Report: Is Oragenics Inc forming bullish engulfing patterns2026 Decliners & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Oragenics, Inc.: Fundamental Analysis and Financial Ratings | UAV0 | US6840236094 - marketscreener.com
OGEN Forecast, Price Target & Analyst Ratings | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
Oragenics (NASDAQ: OGEN) updates S-3/A with auditor consent - Stock Titan
Oragenics Files 2025 Annual Report, Highlights Progress in Concussion Treatment Development - citybuzz -
Oragenics Submits Annual Report Highlighting Fiscal Year 2025 Financials and Research Updates - geneonline.com
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K - The Manila Times
Biotech Oragenics raises $16.5M, clears debt to fund concussion drug trial - Stock Titan
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Oragenics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION - Sahm
Oragenics Initiates First Clinical Site for Phase IIa Trial of Intranasal Concussion Treatment - citybuzz -
Oragenics Inc Initiates Phase Iia Clinical Trial Site Activation - marketscreener.com
Oragenics (OGEN) Advances Phase IIa Clinical Trial of ONP-002 in Australia - GuruFocus
Oragenics begins testing nasal concussion treatment in Australia - Stock Titan
Oragenics Receives Australian HREC Approval to Begin Phase IIa Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury - Minichart
Oragenics Advances Concussion Drug Trial and Explores CNS Asset Acquisitions - TipRanks
Oragenics Explores CNS Asset Acquisitions to Expand Brain Health Pipeline - citybuzz -
Oragenics (OGEN) Eyes Expansion in Central Nervous System Sector - GuruFocus
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION - The Manila Times
Oragenics (OGEN) Receives Approval for Phase IIa Concussion Drug Trial in Australia - GuruFocus
Oragenics Receives HREC Approval for Phase IIa Clinical - GlobeNewswire
Is Oragenics Inc forming bullish engulfing patterns2025 Key Highlights & Daily Momentum Trading Reports - baoquankhu1.vn
Inflation Data: Is Oragenics Inc a strong candidate for buy and holdJuly 2025 Sentiment & High Return Trade Guides - baoquankhu1.vn
Aug Technicals: What is the target price for Oragenics Inc stockPortfolio Performance Report & Momentum Based Trading Signals - baoquankhu1.vn
OGEN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Momentum Shift: Is Oragenics Inc vulnerable to short sellersJuly 2025 Update & Weekly Breakout Stock Alerts - baoquankhu1.vn
How Oragenics Inc. stock trades pre earningsJuly 2025 Pullbacks & Risk Managed Investment Entry Signals - mfd.ru
OGEN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
OGEN Should I Buy - Intellectia AI
Can Oragenics Inc. sustain its profitabilityJuly 2025 Macro Moves & Consistent Return Investment Signals - mfd.ru
Is Oragenics Inc. vulnerable to short sellers2025 Key Lessons & Verified Chart Pattern Signals - mfd.ru
Oragenics previews targeted milestones for 2026 - Yahoo Finance
Oragenics (OGEN) Progresses ONP-002 for Potential $9 Billion Con - GuruFocus
Oragenics Targets Projected $9 Billion Market by Advancing - GlobeNewswire
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy - Yahoo Finance
Portfolio Shifts: What is the next catalyst for Oragenics IncJuly 2025 Closing Moves & Consistent Return Investment Signals - baoquankhu1.vn
Finanzdaten der Oragenics Inc-Aktie (OGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):